ArticleAdvances in radiation oncology
An Automated Workflow to Improve Efficiency in Radiation Therapy Treatment Planning by Prioritizing Organs at Risk.
Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Artificial intelligence in radiation treatment planning: a narrative review from automation to clinical decision support.Translational cancer research · 2026Review
- Inter-Observer variability in organs at risk contouring among radiation therapy students and qualified radiation therapists.Technical innovations & patient support in radiation oncology · 2025Article
- Artificial Intelligence in Head and Neck Surgery.Otolaryngologic clinics of North America · 2024Review
- Knowledge-based quality control of organ delineations in radiation therapy.Medical physics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeManual delineation (MD) of organs at risk (OAR) is time and labor intensive. Auto-delineation (AD) can reduce the need for MD, but because current algorithms are imperfect, manual review and modification is still typically used. Recognizing that many OARs are sufficiently far from important dose levels that they do not pose a realistic risk, we hypothesize that some OARs can be excluded from MD and manual review with no clinical effect. The purpose of this study was to develop a method that automatically identifies these OARs and enables more efficient workflows that incorporate AD without degrading clinical quality. METHODS AND MATERIALS: Preliminary dose map estimates were generated for n = 10 patients with head and neck cancers using only prescription and target-volume information. Conservative estimates of clinical OAR objectives were computed using AD structures with spatial expansion buffers to account for potential delineation uncertainties. OARs with estimated dose metrics below clinical tolerances were deemed low priority and excluded from MD and/or manual review. Final plans were then optimized using high-priority MD OARs and low-priority AD OARs and compared with reference plans generated using all MD OARs. Multiple different spatial buffers were used to accommodate different potential delineation uncertainties.
resultsSixty-seven out of 201 total OARs were identified as low-priority using the proposed methodology, which permitted a 33% reduction in structures requiring manual delineation/review. Plans optimized using low-priority AD OARs without review or modification met all planning objectives that were met when all MD OARs were used, indicating clinical equivalence.
conclusionsPrioritizing OARs using estimated dose distributions allowed a substantial reduction in required MD and review without affecting clinically relevant dosimetry.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.